These results have led to the development of the FLX475 molecule (Flxbio Inc (South San Francisco, CA, USA)) currently being tested in phase 1 clinical trials alone or in combination with anti-PD-1 in advanced cancer (NCT03674567). Here, PDCD1 is linked to cancer.